ADAR1 Capital Management LLC Purchases Shares of 600,999 ARS Pharmaceuticals, Inc. $SPRY

Key Points

• ADAR1 Capital Management acquired 600,999 shares of ARS Pharmaceuticals worth approximately $4.8 million, representing about 0.61% of the company; institutional investors collectively own 68.16% of the stock.
• ARS Pharmaceuticals reported a quarterly loss of $0.63 per share, missing estimates by $0.15, although revenue of $33.66 million exceeded forecasts. The stock opened at $5.72, well below its 52-week high of $14.00.
• Analysts maintain a broadly positive outlook, with a “Moderate Buy” consensus and average price target of $28.20, but the company faces securities litigation allegations related to disclosures about CVS Caremark coverage for its neffy product.

ADAR1 Capital Management LLC acquired a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 600,999 shares of the company's stock, valued at approximately $4,814,000. ADAR1 Capital Management LLC owned approximately 0.61% of ARS Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of ARS Pharmaceuticals by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company's stock worth $56,000 after purchasing an additional 982 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in ARS Pharmaceuticals by 3.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,994 shares of the company's stock valued at $596,000 after purchasing an additional 1,234 shares during the last quarter. ProShare Advisors LLC grew its holdings in ARS Pharmaceuticals by 11.3% during the fourth quarter. ProShare Advisors LLC now owns 15,139 shares of the company's stock worth $176,000 after purchasing an additional 1,532 shares during the period. FAS Wealth Partners Inc. grew its holdings in ARS Pharmaceuticals by 0.9% during the fourth quarter. FAS Wealth Partners Inc. now owns 202,407 shares of the company's stock worth $2,358,000 after purchasing an additional 1,787 shares during the period. Finally, Osaic Holdings Inc. increased its position in ARS Pharmaceuticals by 52.8% during the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company's stock worth $91,000 after buying an additional 1,803 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company's stock.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ:SPRY opened at $5.72 on Wednesday. The company's 50 day simple moving average is $7.07 and its 200 day simple moving average is $8.08. The stock has a market capitalization of $568.85 million, a price-to-earnings ratio of -2.62 and a beta of 0.98. The company has a debt-to-equity ratio of 13.72, a current ratio of 3.48 and a quick ratio of 3.28. ARS Pharmaceuticals, Inc. has a 1 year low of $4.91 and a 1 year high of $14.00.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.15). ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%.The business had revenue of $33.66 million for the quarter, compared to analyst estimates of $31.32 million. As a group, research analysts predict that ARS Pharmaceuticals, Inc. will post -1.9 EPS for the current fiscal year.

Key Headlines Impacting ARS Pharmaceuticals

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Neutral Sentiment: Multiple law firms—including Rosen, Faruqi & Faruqi, Pomerantz, Schall Brown & Schwartz, Levi & Korsinsky, Kaplan Fox, and Bronstein Gewirtz & Grossman—reminded investors that October 5, 2026 is the deadline to seek appointment as lead plaintiff in the securities litigation. These announcements are largely procedural and duplicate one another. Rosen investor notice
• Negative Sentiment: The lawsuit alleges that ARS Pharmaceuticals misrepresented the timing of expanded CVS Caremark coverage for neffy, its needle-free epinephrine product, before a reported single-day 23.9% share decline. If the claims advance, the company could face litigation costs, potential damages, and reputational pressure. The allegations have not been proven. Shareholder lawsuit alert
• Neutral Sentiment: A reported August short-interest update showed zero shares sold short and a zero-day days-to-cover ratio, but the figures appear inconsistent with the accompanying claim of a significant increase and should not be treated as a reliable trading signal.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SPRY. Weiss Ratings lowered shares of ARS Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday, August 17th. Cantor Fitzgerald lifted their target price on shares of ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, May 28th. Leerink Partners decreased their price target on shares of ARS Pharmaceuticals from $25.00 to $24.00 and set an "outperform" rating on the stock in a research note on Thursday, June 25th. Finally, Wall Street Zen raised shares of ARS Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, May 16th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $28.20.

Insider Transactions at ARS Pharmaceuticals

In other news, insider Alexander A. Fitzpatrick sold 3,355 shares of ARS Pharmaceuticals stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $33,550.00. Following the completion of the transaction, the insider directly owned 90,910 shares of the company's stock, valued at approximately $909,100. This trade represents a 3.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Karas sold 25,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $250,000.00. Following the completion of the sale, the insider owned 12,176 shares of the company's stock, valued at approximately $121,760. The trade was a 67.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 33.80% of the stock is owned by company insiders.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.

Want to see what other hedge funds are holding SPRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source